WADA S2
This substance falls under WADA S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics). If you are subject to anti-doping rules, this category of substances is prohibited at all times.
FDA Safety Flag
The FDA has identified this substance as one that may present significant safety risks when used in compounding, including concerns about immunogenicity, impurity characterization, and/or insufficient safety information.
Evidence visual
Thymosin Beta-4 evidence and risk matrix
intermediate researcher fit
Evidence
Tier B-C
Risk
med high
Regulatory
investigational
WADA
S2
FDA
flagged
Route
topical
Mixed evidence profile. Useful for comparison, not a standalone protocol decision.
Overview
Thymosin beta-4 is a 43-amino-acid peptide involved in cell migration, angiogenesis, and tissue repair. Clinical ophthalmic studies using topical 0.1% formulations (RGN-259) report safety and improved epithelial healing in corneal disorders. Systemic claims have weaker clinical grounding. WADA classifies thymosin-β4 derivatives under growth factor modulators.
Decision path
Where Thymosin Beta-4 fits in the research path.
Use the evidence and risk profile first, then compare vendors and run the quiz before turning this compound into a protocol decision.
01
Read evidence
02
Check risk
03
Compare options
04
Build plan
Peptide research path
Decide whether Thymosin Beta-4 belongs in your plan.
Use the quiz before choosing a compound, vendor, or PDF. It routes by goal, experience, budget, safety flags, and monitoring comfort.
Research Details
Actin-sequestering protein with roles in cell migration, angiogenesis, and tissue repair across multiple active domains.
topical, subcutaneous
Clinical ophthalmic: topical 0.1% formulation. Systemic dosing not well established in humans.
Ophthalmic: improved corneal epithelial healing. Systemic: wound healing signals in preclinical models.
Corneal healing studies: days to weeks; systemic repair claims are less well-timed.
Limited formal contraindication data.
Human ophthalmic safety reported as acceptable in trials; systemic safety requires caution.
Limited formal interaction studies; treat as unknown outside studied settings.
Cost at a glance
Typical cycle cost
$192.00
Estimated monthly
$96.00
Protocol style
6-10 week phase
Phase-based
Estimate confidence
High confidence
Assumes roughly 12 mg–24 mg per cycle, using 1 tracked affiliated listing.
Reflects multi-week repair protocols instead of a one-month estimate.
Known Interactions
Information provided for educational and research reference only. Not medical advice. Not for diagnosing, treating, curing, or preventing disease. Products referenced are labeled Research Use Only (RUO) by vendors; not for human or veterinary use.
Sources and review notes
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks - U.S. Food and Drug Administration - accessed 2026-05-15
Used for FDA compounding-risk context and peptide safety flags.
- The Prohibited List - World Anti-Doping Agency - accessed 2026-05-15
Used for athlete-facing WADA risk and peptide-class restrictions.
- Peptide therapeutics: current status and future directions - PubMed / Nature Reviews Drug Discovery - accessed 2026-05-15
Used for broad peptide-therapeutics background and evidence framing.
Personalized peptide routing
Find the right path for Thymosin Beta-4.
Take the quiz before choosing a compound, vendor, or PDF. We match your goal, experience, budget, and monitoring comfort to the next best step in the funnel.
- Goal-matched compound and protocol recommendations.
- Budget and sourcing filters before you leave the site.
- PDF unlocks shown after your personalized result.